search

1-20 of 65

Save search

Sort by

Sort Order Select

2 3 4

Journal Article

ACTR-01. SAFETY ANALYSES OF TUMOR TREATING FIELDS IN COMBINATION WITH LOMUSTINE IN THE EF14 PHASE 3 CLINICAL STUDY

PDF

Adrian Kinzel and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi11, https://doi.org/10.1093/neuonc/noy148.038

Published: 05 November 2018

Journal Article

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS

PDF

Barbara Fisher and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi11, https://doi.org/10.1093/neuonc/noy148.039

Published: 05 November 2018

Journal Article

ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA

PDF

Lisa Rogers and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi11–vi12, https://doi.org/10.1093/neuonc/noy148.040

Published: 05 November 2018

Journal Article

ACTR-06. INITIAL RESULTS OF A PHASE I STUDY OF PROCASPASE ACTIVATING CCOMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE FOR RECURRENT MALIGNANT GLIOMA

PDF

Martin Nicholas and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi12, https://doi.org/10.1093/neuonc/noy148.041

Published: 05 November 2018

Journal Article

ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN

PDF

Xiao-Tang Kong and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi13, https://doi.org/10.1093/neuonc/noy148.045

Published: 05 November 2018

Journal Article

ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

PDF

Vinay Puduvalli and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi13, https://doi.org/10.1093/neuonc/noy148.047

Published: 05 November 2018

Journal Article

ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

PDF

Brian Alexander and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi13–vi14, https://doi.org/10.1093/neuonc/noy148.048

Published: 05 November 2018

Journal Article

ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY

PDF

Andrew J Brenner and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi14–vi15, https://doi.org/10.1093/neuonc/noy148.051

Published: 05 November 2018

Journal Article

ACTR-22. A PHASE I STUDY OF CYTOSINE DEAMINASE-EXPRESSING NEURAL STEM CELLS (CD-NSCs) ADMINISTERED INTRACRANIALLY AND IN COMBINATION WITH ORAL 5-FLUOROCYTOSINE (5-FC) AND LEUCOVORIN IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

PDF

Jana Portnow and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi16, https://doi.org/10.1093/neuonc/noy148.056

Published: 05 November 2018

Journal Article

ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

PDF

Brandon Konkel and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi16, https://doi.org/10.1093/neuonc/noy148.058

Published: 05 November 2018

Journal Article

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

PDF

Kent Shih and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi17–vi18, https://doi.org/10.1093/neuonc/noy148.063

Published: 05 November 2018

Journal Article

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

PDF

Ingo Mellinghoff and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi18, https://doi.org/10.1093/neuonc/noy148.064

Published: 05 November 2018

Journal Article

ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME

PDF

Jacob Leary and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi19, https://doi.org/10.1093/neuonc/noy148.068

Published: 05 November 2018

Journal Article

ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

PDF

Frank Saran and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi20, https://doi.org/10.1093/neuonc/noy148.071

Published: 05 November 2018

Journal Article

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

PDF

Daniela A Bota and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi20, https://doi.org/10.1093/neuonc/noy148.073

Published: 05 November 2018

Journal Article

ACTR-52. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY – A SAFETY ANALYSIS

PDF

Adrian Kinzel and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi23, https://doi.org/10.1093/neuonc/noy148.084

Published: 05 November 2018

Journal Article

ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE

PDF

Alessia Pellerino and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.086

Published: 05 November 2018

Journal Article

ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414

PDF

Hui Gan and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi24, https://doi.org/10.1093/neuonc/noy148.087

Published: 05 November 2018

Journal Article

ACTR-63. TREATMENT AND SURVIVAL OF PATIENTS WITH LOWER GRADE GLIOMA ACCORDING TO THE 2007 AND THE 2016 WHO CLASSIFICATION: A RETROSPECTIVE ANALYSIS OF 423 PATIENTS

PDF

Eike Steidl and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi25–vi26, https://doi.org/10.1093/neuonc/noy148.093

Published: 05 November 2018

Journal Article

ACTR-67. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN (ONIVYDE) USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: RESULTS THUS FAR

PDF

Karishma Kumar and others

Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi26–vi27, https://doi.org/10.1093/neuonc/noy148.097

Published: 05 November 2018

2 3 4

Modify your search

Availability

NARROW

Format

Type

Section

Publication date

ACTR-01. SAFETY ANALYSES OF TUMOR TREATING FIELDS IN COMBINATION WITH LOMUSTINE IN THE EF14 PHASE 3 CLINICAL STUDY

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS

ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA

ACTR-06. INITIAL RESULTS OF A PHASE I STUDY OF PROCASPASE ACTIVATING CCOMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE FOR RECURRENT MALIGNANT GLIOMA

ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN

ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY

ACTR-22. A PHASE I STUDY OF CYTOSINE DEAMINASE-EXPRESSING NEURAL STEM CELLS (CD-NSCs) ADMINISTERED INTRACRANIALLY AND IN COMBINATION WITH ORAL 5-FLUOROCYTOSINE (5-FC) AND LEUCOVORIN IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME

ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

ACTR-52. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY – A SAFETY ANALYSIS

ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE

ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414

ACTR-63. TREATMENT AND SURVIVAL OF PATIENTS WITH LOWER GRADE GLIOMA ACCORDING TO THE 2007 AND THE 2016 WHO CLASSIFICATION: A RETROSPECTIVE ANALYSIS OF 423 PATIENTS

ACTR-67. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN (ONIVYDE) USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: RESULTS THUS FAR

Email alerts

Modify your search

Publication date

ACTR-01. SAFETY ANALYSES OF TUMOR TREATING FIELDS IN COMBINATION WITH LOMUSTINE IN THE EF14 PHASE 3 CLINICAL STUDY Free

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS Free

ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA Free

ACTR-06. INITIAL RESULTS OF A PHASE I STUDY OF PROCASPASE ACTIVATING CCOMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE FOR RECURRENT MALIGNANT GLIOMA Free

ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN Free

ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS Free

ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM Free

ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY Free

ACTR-22. A PHASE I STUDY OF CYTOSINE DEAMINASE-EXPRESSING NEURAL STEM CELLS (CD-NSCs) ADMINISTERED INTRACRANIALLY AND IN COMBINATION WITH ORAL 5-FLUOROCYTOSINE (5-FC) AND LEUCOVORIN IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Free

ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE Free

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM) Free

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION Free

ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME Free

ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) Free

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS Free

ACTR-52. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY – A SAFETY ANALYSIS Free

ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE Free

ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414 Free

ACTR-63. TREATMENT AND SURVIVAL OF PATIENTS WITH LOWER GRADE GLIOMA ACCORDING TO THE 2007 AND THE 2016 WHO CLASSIFICATION: A RETROSPECTIVE ANALYSIS OF 423 PATIENTS Free

ACTR-67. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN (ONIVYDE) USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: RESULTS THUS FAR Free

Email alerts

This Feature Is Available To Subscribers Only

ACTR-01. SAFETY ANALYSES OF TUMOR TREATING FIELDS IN COMBINATION WITH LOMUSTINE IN THE EF14 PHASE 3 CLINICAL STUDY

ACTR-02. NRG ONCOLOGY/RTOG 0424: LONG-TERM RESULTS OF A PHASE II STUDY OF TEMOZOLOMIDE-BASED CHEMORADIOTHERAPY REGIMEN FOR HIGH-RISK LOW-GRADE GLIOMAS

ACTR-03. A FEASIBILITY TRIAL OF THE MODIFIED ATKINS DIET AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA

ACTR-06. INITIAL RESULTS OF A PHASE I STUDY OF PROCASPASE ACTIVATING CCOMPOUND-1 (PAC-1) IN COMBINATION WITH TEMOZOLOMIDE FOR RECURRENT MALIGNANT GLIOMA

ACTR-10. A RANDOMIZED, PHASE I/II TRIAL OF IXAZOMIB IN COMBINATION WITH STANDARD THERAPY FOR UPFRONT TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MGMT METHYLATED GLIOBLASTOMA (GBM) STUDY DESIGN

ACTR-13. A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS

ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY

ACTR-22. A PHASE I STUDY OF CYTOSINE DEAMINASE-EXPRESSING NEURAL STEM CELLS (CD-NSCs) ADMINISTERED INTRACRANIALLY AND IN COMBINATION WITH ORAL 5-FLUOROCYTOSINE (5-FC) AND LEUCOVORIN IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA

ACTR-25. UPDATED RESULTS FROM A PROSPECTIVE, RANDOMIZED PHASE 2 STUDY IN PATIENTS WITH FIRST RELAPSE OF HIGH-GRADE ASTROCYTOMA USING TVB-2640 IN COMBINATION WITH AVASTIN VERSUS AVASTIN ALONE

ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)

ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION

ACTR-35. MOLECULAR MATCHMAKING: EFFICACY OF EARLY CLINICAL TRIALS GUIDED BY NEXT-GENERATION SEQUENCING IN PATIENTS WITH GLIOBLASTOMA MULTIFORME

ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

ACTR-52. TUMOR TREATING FIELDS (TTFIELDS) IN COMBINATION WITH LOMUSTINE (CCNU) IN THE EF-14 PHASE 3 CLINICAL STUDY – A SAFETY ANALYSIS

ACTR-54. PATTERN OF RECURRENCE AND IMPACT ON SURVIVAL OF SALVAGE THERAPIES IN LOW-GRADE GLIOMAS FOLLOWING DOSE-DENSE TEMOZOLOMIDE

ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414

ACTR-63. TREATMENT AND SURVIVAL OF PATIENTS WITH LOWER GRADE GLIOMA ACCORDING TO THE 2007 AND THE 2016 WHO CLASSIFICATION: A RETROSPECTIVE ANALYSIS OF 423 PATIENTS

ACTR-67. A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN (ONIVYDE) USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS: RESULTS THUS FAR